ATH alterity therapeutics limited

Ann: Appendix 4E Preliminary Final Report, page-11

  1. 141 Posts.
    lightbulb Created with Sketch. 18
    Getting into a partnership at this stage would be a terrible move. Any deal now would be a Lowball offer, say 10M cash upfront for a right to the future of this drug. Say goodbye to any better deals following readouts when the potential of this drug to be a MSA and defacto PD modifying drug (if it works) will be apparent.

    as long as they get to readout, even if they are running on financial fumes, I am happy.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
-0.001(4.55%)
Mkt cap ! $95.83M
Open High Low Value Volume
1.1¢ 1.1¢ 1.1¢ $9.29K 855.4K

Buyers (Bids)

No. Vol. Price($)
34 14615464 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 13635816 11
View Market Depth
Last trade - 10.32am 18/06/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.